An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Registration Number
- NCT00932893
- Lead Sponsor
- Pfizer
- Brief Summary
This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 347
- histologically or cytologically proven diagnosis of non-small cell lung cancer
- positive for the ALK fusion gene (test provided by a central laboratory)
- must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug
- tumors must be measurable
- prior treatment with PF-02341066
- current treatment in another clinical trial
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Pemetrexed or Docetaxel Docetaxel Investigator selection of either pemetrexed or docetaxel as the active comparator PF-02341066 PF-02341066 - Pemetrexed or Docetaxel Pemetrexed Investigator selection of either pemetrexed or docetaxel as the active comparator
- Primary Outcome Measures
Name Time Method Progression-Free Survival (PFS) Randomization until progressive disease (PD) or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks) PFS: Time in months from randomization to first documentation of objective disease progression as determined by independent radiology review or to death due to any cause, whichever occurred first. PFS was calculated as (first event date minus the date of randomization plus 1) divided by 30.4. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria version 1.1 (RECIST v1.1), as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
- Secondary Outcome Measures
Name Time Method Overall Survival (OS) Randomization until death (up to 4.5 years) OS: Time in months from randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4.
Overall Survival Probability at Months 6 and 12 Month 6, 12 Overall survival probability at Month 6 and 12 was defined as the probability of survival at 6 and 12 months respectively, after the randomization of study treatment. The survival probability was estimated using the Kaplan-Meier method.
Duration of Response (DR) Randomization until PD or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks) Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7.02. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
Percentage of Participants With Disease Control at Week 6 Week 6 Disease control: participants with CR, PR, or stable disease (SD) according to RECIST v1.1. CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis). PR: at least 30 % decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. Disease control is based on independent radiology review.
Time to Tumor Response (TTR) Randomization until PD or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks) Time from date of randomization to first documentation of objective tumor response. TTR was calculated for the subgroup of participants with objective tumor response. Objective tumor response was defined as CR or PR according to RECIST v1.1. CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis). PR: at least 30 % decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Baseline, Day (D) 1 of each cycle (C) until disease progression, end of treatment (EOT, up to 112 weeks) EORTC QLQ-C30: included global health status/quality of life (QoL), functional scales (physical, role, cognitive, emotional, and social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score for Global Qol/functional scales=better level of QoL/functioning or higher score for symptom scale=greater degree of symptoms.
Percentage of Participants With Disease Control at Week 12 Week 12 Disease control: participants with CR, PR, or SD according to RECIST v1.1. CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis). PR: at least 30 % decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) Baseline, Day 1 of each cycle until disease progression, end of treatment (up to 112 weeks) EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
Plasma Concentration of Crizotinib Pre-dose on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of Cycles 2, 3, 5 Only participants receiving crizotinib were to be analyzed for this outcome measure as per planned analysis.
Plasma Concentration of Soluble c-Met Ectodomain and Hepatocyte Growth Factor Scatter Proteins Pre-dose on Day 1 of Cycle 1, 2 to 6 hours post-dose on Day 1 of Cycle 2, end of treatment (up to 112 weeks) Descriptive statistics (absolute value and change from baseline as measured by ratio to baseline) for each best overall response category (CR, PR, SD, PD or combined) have been used to summarize the data from optional soluble c-Met ectodomain assays for crizotinib treated patients.
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) Baseline, Day 1 of each cycle until disease progression, end of treatment (up to 112 weeks) QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: 1 'Not at All' to 4 'Very Much'. Scores averaged, transformed to 0-100 scale; higher symptom score = greater degree of symptoms.
Percentage of Participants With Objective Response (OR) Randomization until PD or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks) Percentage of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to RECIST v1.1. CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 millimeter \[mm\] short axis). PR: at least 30 percent (%) decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. Objective response is based on independent radiology review.
Number of Participants With Categorical Maximum QTcF for Crizotinib Pre-dose on Day 1 of Cycle 1, 2 to 6 hours post-dose on Day 1 of Cycle 1, 2 QT interval corrected using Fridericia's formula (QTcF): QT interval (time corresponding to the beginning of depolarization to re-polarization of the ventricles) divided by cube root of RR interval. Maximum QTcF was categorized as less than (\<) 450 milliseconds (msec), 450 msec to \<480 msec, 480 msec to \<500 msec, and more than or equal to (\>=) 500 msec. A participant is reported only once under the maximum QTcF interval observed at any of the time-points. Only participants receiving crizotinib were to be analyzed for this outcome measure as per planned analysis.
Time to Deterioration (TTD) in Participant Reported Pain, Dyspnea, and Cough Baseline up to end of treatment (up to 112 weeks) TTD in pain (pain in chest from European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer \[EORTC QLQ-LC13\]), dyspnea (from EORTC QLQ-LC13), or cough (from EORTC QLQ-LC13) symptoms was defined as the time from randomization to the earliest time the participant's score showed a 10 point or higher increase from baseline in any of the three symptoms from the instrument. The transformed score of pain, dyspnea, and cough symptom scales of EORTC QLQ-LC13 range from 0 to 100, greater scores = higher symptom severity.
Trial Locations
- Locations (244)
UCLA Hematology Oncology
🇺🇸Los Angeles, California, United States
The Ohio State University Hospital East
🇺🇸Columbus, Ohio, United States
University of Pittsburgh Medical Center
🇺🇸Pittsburgh, Pennsylvania, United States
RSM Durham Regional Cancer Centre
🇨🇦Oshawa, Ontario, Canada
Brigham and Women's Hospital
🇺🇸Boston, Massachusetts, United States
Beth Isreal Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Seattle Cancer Care Alliance
🇺🇸Seattle, Washington, United States
University of Washington Medical Center
🇺🇸Seattle, Washington, United States
Investigational Drug Service
🇺🇸Seattle, Washington, United States
Lux Med. Sp.z o.o
🇵🇱Warszawa, Poland
James Care in Kenny
🇺🇸Columbus, Ohio, United States
Abramson Cancer Center of the University of Pennsylvania at Perelman Center for Advanced Medicine
🇺🇸Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center-Shadyside
🇺🇸Pittsburgh, Pennsylvania, United States
Sydney Cancer Centre
🇦🇺Camperdown, New South Wales, Australia
Jewish General Hospital
🇨🇦Montreal, Quebec, Canada
Fundacao Pio XII Hospital de Cancer de Barretos
🇧🇷Barretos, SP, Brazil
Instituto do Câncer de São Paulo "Octavio Frias de Oliveira" - ICESP
🇧🇷Sao Paulo, SP, Brazil
Cleveland Clinic
🇺🇸Cleveland, Ohio, United States
Swedish Cancer Institute
🇺🇸Seattle, Washington, United States
Centre Francois Baclesse
🇫🇷Caen Cedex 05, France
Groupe Hospitalier Cochin
🇫🇷Paris Cedex 14, France
Fundacao Hospital Amaral Carvalho
🇧🇷Jau, Sao Paulo, Brazil
Westdeutsches Tumorzentrum, Universitaetsklinikum Essen, Innere Klinik - Tumorforschung
🇩🇪Essen, Germany
Royal Adelaide Hospital, Department of Medical Oncology
🇦🇺Adelaide, South Australia, Australia
Hospital Sao Lucas da PUCRS
🇧🇷Porto Alegre, RS, Brazil
Tennessee Oncology, PLLC
🇺🇸Smyrna, Tennessee, United States
The Ohio State University James Cancer Hospital and Solove Research Institute
🇺🇸Columbus, Ohio, United States
Dr. Dana Blakolmer and Associates
🇨🇦Oshawa, Ontario, Canada
Nucleo de Oncologia da Bahia
🇧🇷Salvador, BA, Brazil
SUNY Upstate Medical University
🇺🇸Syracuse, New York, United States
Peter MacCallum Cancer Centre, Division of Haematology and Medical Oncology
🇦🇺East Melbourne, Victoria, Australia
Vincent Armenio, MD
🇺🇸East Providence, Rhode Island, United States
Nanjing Bayi Hospital
🇨🇳Nanjing, Jiangsu, China
The Ottawa Hospital Cancer Centre
🇨🇦Ottawa, Ontario, Canada
Penn State Milton S. Hershey Medical Center, Penn State Hershey Cancer Institute
🇺🇸Hershey, Pennsylvania, United States
UMBAL "Tsaritsa Yoanna - ISUL", Klinika po onkoterapiya
🇧🇬Sofia, Bulgaria
MBAL Voennomeditsinska Academia, MMA HAT Sofia
🇧🇬Sofia, Bulgaria
Centre Antoine Lacassagne
🇫🇷NICE Cedex 2, France
MVZ Prof. Mathey, Pfrof. Schofer GmbH
🇩🇪Hamburg, Germany
Klinikum der Universitaet Muenchen, Medizinische Klink - Innenstadt, Pneumologie
🇩🇪Muenchen, Germany
Universitaetsklinik Carl-Gustav-Carus Dresden
🇩🇪Dresden, Germany
Cancer Institute and Hospital Chinese Academy of Medical Sciences and PUMC
🇨🇳Beijing, China
General Hospital of Chest Diseases of Athens "Sotiria"
🇬🇷Athens, Greece
Ospedale Versilia, Oncologia Medica
🇮🇹Lido di Camaiore (LU), Italy
Oncologia Medica A
🇮🇹Genova, Italy
Centre Georges-François Leclerc
🇫🇷DIJON Cedex, France
Pr Fabrice BARLESI
🇫🇷Marseille Cedex 20, France
Hopital Tenon / Service de Pneumologie
🇫🇷Paris cedex 20, France
Institut Gustave Roussy
🇫🇷Villejuif, France
Krankenhaus Grosshansdorf, Zentrum fuer Pneumologie und Thoraxchirurgie
🇩🇪Grosshansdorf, Germany
Seoul National University Hospital / Department of Internal Medicine
🇰🇷Seoul, Korea, Republic of
Hopital Albert Michallon
🇫🇷Grenoble Cedex 09, France
Nuffield Health Wessex Hospital
🇬🇧Eastleigh, United Kingdom
Centre Rene Gauducheau / Service d'Oncologie Medicale
🇫🇷St Herblain Cedex, France
Hospital General Universitari Vall D´Hebron
🇪🇸Barcelona, Spain
Complexo Hospitalario Universitario A Coruña. Hospital Teresa Herrera (Materno-Infantil)
🇪🇸A Coruña, Spain
HSK Dr.- Horst-Schmidt-Kliniken, Innere Medizin III Haematologie, Onkologie, Palliativmedizin
🇩🇪Wiesbaden, Germany
Semmelweis Egyetem Pulmonologia Intezet
🇭🇺Budapest, Hungary
National Cancer Center Hospital
🇯🇵Chuo-ku, Tokyo, Japan
Royal Marsden Hospital
🇬🇧London, United Kingdom
A.O. di Rilievo Nazionale e di Alta Specialita - S. G. Moscati
🇮🇹Avellino, Italy
Cancer and Haematology Centre,
🇬🇧Oxford, United Kingdom
Klinikum der Universitaet zu Koeln, Klinik I fuer Innere Medizin
🇩🇪Koeln, Germany
Hospital Universitario Marques de Valdecilla
🇪🇸Santander, Spain
Thoraxklinik am Universitaetsklinikum Heidelberg, Internistische Onkologie der Thoraxtumoren
🇩🇪Heidelberg, Germany
University General Hospital of Heraklion/ Department of Clinical Oncology
🇬🇷Heraklion, Crete, Greece
Hospital Del Mar
🇪🇸Barcelona, Spain
Ospedale San Luca
🇮🇹Lucca, Italy
The Alexandra Hospital
🇬🇧Cheshire, United Kingdom
Aichi cancer center central hospital
🇯🇵Nagoya, Aichi, Japan
Kinki University Hospital
🇯🇵Osakasayama-shi, Osaka, Japan
Shizuoka Cancer Center
🇯🇵Sunto-gun, Shizuoka, Japan
National Kyushu Cancer Center
🇯🇵Fukuoka, Japan
Samsung MedicaCenter,SungkyunkwanUnivSchoolofMedicine,Div. of Hematology-Oncology, Dep. of Medicine
🇰🇷Seoul, Korea, Republic of
National Cancer Center, Center for Lung Cancer
🇰🇷Goyang-si, Gyeonggi-do, Korea, Republic of
Hospital Universitario Central de Asturias
🇪🇸Oviedo, Asturias, Spain
Royal Free Hospital
🇬🇧London, United Kingdom
Kings College London at Guy's Hospital
🇬🇧London, United Kingdom
Institut Catala Doncologia - Hospital Duran I Reynals
🇪🇸L'hospitalet de Llobregat, Barcelona, Spain
Karolinska Universitetssjukhuset, Onkologiska kliniken
🇸🇪Stockholm, Sweden
Taipei Veterans General Hospital, Chest Department
🇨🇳Taipei, Taiwan
Christie Hospital NHS Trust, Department of Medical Oncology
🇬🇧Manchester, United Kingdom
Southampton University Hospitals NHS Trust
🇬🇧Southampton, United Kingdom
SUN Yat-Sen University Cancer Center
🇨🇳Guangzhou, Guangdong, China
Guangdong General Hospital
🇨🇳Guangzhou, Guangdong, China
307 Hospital of PLA
🇨🇳Beijing, China
Shanghai Chest Hospital/Department of Pulmonary Medicine
🇨🇳Shanghai, China
Shanghai Chest Hospital
🇨🇳Shanghai, China
Zhongshan Hospital Fudan University / Respiratory Department
🇨🇳Shanghai, China
Shanghai Pulmonary Hospital/Dept. of Oncology
🇨🇳Shanghai, China
MDOZS Plovdiv EOOD; Parvo vatreshno himioterapevtichno otdelenie
🇧🇬Plovdiv, Bulgaria
Montreal General Hospital
🇨🇦Montreal, Quebec, Canada
Alberta Health Services, Holy Cross Site
🇨🇦Calgary, Alberta, Canada
Department of Medical Oncology
🇮🇪Galway, Ireland
Dr. Leon Richard Oncology Centre
🇨🇦Moncton, New Brunswick, Canada
Tom Baker Cancer Centre
🇨🇦Calgary, Alberta, Canada
General Hospital of Thessaloniki Georgios Papanikolaou, Lung Cancer Neoplasia Research Department
🇬🇷Exohi, Thessaloniki, Greece
Pest Megyei Tudogyogyintezet, III. Osztaly
🇭🇺Torokbalint, Hungary
Merlin Park Imaging Centre
🇮🇪Galway, Ireland
Klinika Onkologii i Radioterapii
🇵🇱Gdansk, Poland
Republican Clinical Oncology Dispensary of the Ministry of Health of Tatarstan Republic
🇷🇺Kazan, Russian Federation
Hospital Universitari Germans Trias I Pujol
🇪🇸Badalona, Barcelona, Spain
State Institution "National Cancer Research Center named after N.N. Blokhin' RAMS"
🇷🇺Moscow, Russian Federation
Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc
🇵🇱Olsztyn, Poland
Centralna Izba Przyjec Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy
🇵🇱Otwock, Poland
Oddzial Onkologii Klinicznej z Pododdzialem Dziennej Chemioterapii
🇵🇱Poznan, Poland
Zaklad Diagnostyki Obrazowej
🇵🇱Poznan, Poland
City Clinical Oncology Dispensary
🇷🇺St. Petersburg, Russian Federation
Saint-Petersburg State Medical University named after I.P.Pavlov of Roszdrav
🇷🇺Saint-Petersburg, Russian Federation
Pracownia Tomografii Komputerowej "ALL MEDI" Sp. z o.o.
🇵🇱Otwock, Poland
Research Institute of Pulmonology
🇷🇺Saint-Peterburg, Russian Federation
National Taiwan University Hospital, Department of Internal Medicine
🇨🇳Taipei, Taiwan
Consorcio Hospitalario Parc Tauli
🇪🇸Sabadell, Barcelona, Spain
UCSD Medical Center- Hillcrest
🇺🇸San Diego, California, United States
Indiana University Hospital
🇺🇸Indianapolis, Indiana, United States
Indiana University Melvin and Bren Simon Cancer Center
🇺🇸Indianapolis, Indiana, United States
Ship Drug to: Investigational Drug Services
🇺🇸Indianapolis, Indiana, United States
Wishard Memorial Hospital
🇺🇸Indianapolis, Indiana, United States
Springmill Medical Clinic
🇺🇸Indianapolis, Indiana, United States
Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
Oregon Health and Science University
🇺🇸Portland, Oregon, United States
Sarah Cannon Research Institute
🇺🇸Nashville, Tennessee, United States
The Vanderbilt Cancer Clinic
🇺🇸Nashville, Tennessee, United States
The Vanderbilt Chemo Pharmacy
🇺🇸Nashville, Tennessee, United States
Unita' Operativa Complessa di Pneumologia Oncologica I, Padiglione Flaiani
🇮🇹Roma, Italy
Azienda Ospedaliero-Universitaria Careggi
🇮🇹Firenze, Italy
Centro C.O.E.S., A.O. San Giovanni Battista Le Molinette
🇮🇹Torino, Italy
Dipartimento Oncologia Medica, UO Medicina 1Q A, Unita' Nuovi Farmaci e Terapie Innovative
🇮🇹Milano, Italy
Istituto Europeo di Oncologia IRCCS
🇮🇹Milano, Italy
Ospedale Niguarda Ca' Granda Dipartimento Oncologico, SC Divisione di Oncologia Medica Falk
🇮🇹Milano, Italy
Azienda Ospedaliera Universitaria San Luigi Gonzaga
🇮🇹Orbassano (TO), Italy
Nuovo Ospedale San Gerardo
🇮🇹Monza, Italy
SC Oncologia Medica, Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia
🇮🇹Perugia, Italy
Instituto Nacional de Câncer - INCA
🇧🇷Rio de Janeiro, RJ, Brazil
Associacao Hospital de Caridade de Ijui
🇧🇷Ijui, RS, Brazil
Irmandade da Santa Casa de Misericordia de Porto Alegre
🇧🇷Porto Alegre, RS, Brazil
Fundacao Antonio Prudente
🇧🇷Sao Paulo, SP, Brazil
Pius-Hospital Oldenburg
🇩🇪Oldenburg, Germany
Hospital Universitario Virgen Del Rocio
🇪🇸Sevilla, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Unviersity of Colorado Hospital, Anschutz Cancer Pavilion
🇺🇸Aurora, Colorado, United States
Unviersity of Colorado Hospital, Anschutz Inpatient Pavilion
🇺🇸Aurora, Colorado, United States
H Lee Moffitt Cancer Center & Research Institute
🇺🇸Tampa, Florida, United States
Penn Presbyterian Medical Center
🇺🇸Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
Pharma Resource
🇺🇸East Providence, Rhode Island, United States
The University of Texas
🇺🇸Houston, Texas, United States
Comprehensive Blood and Cancer Center
🇺🇸Bakersfield, California, United States
University of Arkansas for Medical Research, Winthrop Rockefeller Cancer Institute
🇺🇸Little Rock, Arkansas, United States
Tower Cancer Research Foundation
🇺🇸Beverly Hills, California, United States
UCSD Medical Center -La Jolla
🇺🇸La Jolla, California, United States
Tower Hematology Oncology Medical Group
🇺🇸Beverly Hills, California, United States
Moores UC San Diego Cancer Center
🇺🇸La Jolla, California, United States
Drug Shipping Address: [IRB# 10-001530] Ronald Reagan UCLA
🇺🇸Los Angeles, California, United States
Ronald Reagan UCLA Medical Center
🇺🇸Los Angeles, California, United States
UCLA Ophthalmic Oncology Center
🇺🇸Los Angeles, California, United States
University of California-Los Angeles
🇺🇸Los Angeles, California, United States
Ship Drug To : Kevin Kong- University of California, Irvine-Pharmacy
🇺🇸Orange, California, United States
University of California, Irvine-Medical Center
🇺🇸Orange, California, United States
Stanford University-Cancer Center
🇺🇸Palo Alto, California, United States
Santa Monica-UCLA Medical Center and Orthopaedic Hospital
🇺🇸Santa Monica, California, United States
Redwood Regional Medical Group, Inc.
🇺🇸Santa Rosa, California, United States
University of Colorado Denver (CTRC)
🇺🇸Aurora, Colorado, United States
Drug Shipment: University of Colorado Cancer Center, Anschutz Cancer Pavilion
🇺🇸Aurora, Colorado, United States
Kaiser Permanente
🇺🇸Lafayette, Colorado, United States
Memorial Cancer Institute
🇺🇸Hollywood, Florida, United States
Cancer Center of South Florida Foundation, Inc.
🇺🇸Lake Worth, Florida, United States
Emory University Hospital
🇺🇸Atlanta, Georgia, United States
Georgia Cancer Specialists - Stemmer
🇺🇸Decatur, Georgia, United States
Emory Clinic
🇺🇸Atlanta, Georgia, United States
Emory University Hospital Midtown
🇺🇸Atlanta, Georgia, United States
Emory University Clinic
🇺🇸Atlanta, Georgia, United States
Winship Cancer Institution
🇺🇸Atlanta, Georgia, United States
Georgia Cancer Specialists-Administrative Annex
🇺🇸Atlanta, Georgia, United States
Cancer Research Center of Hawaii
🇺🇸Honolulu, Hawaii, United States
Georgia Cancer Specialists-Macon
🇺🇸Macon, Georgia, United States
Georgia Cancer Specialists-Kennestone
🇺🇸Marietta, Georgia, United States
Georgia Cancer Specialists
🇺🇸Sandy Springs, Georgia, United States
Hawaii Medical Center East
🇺🇸Honolulu, Hawaii, United States
OnCare Hawaii, Inc.
🇺🇸Honolulu, Hawaii, United States
Rush University Medical Center
🇺🇸Chicago, Illinois, United States
University of Chicago Medical Center
🇺🇸Chicago, Illinois, United States
Ingalls Memorial Hospital (Drug Shipment Only)
🇺🇸Harvey, Illinois, United States
Monroe Medical Associates
🇺🇸Munster, Indiana, United States
The Community Hospital
🇺🇸Munster, Indiana, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
🇺🇸Baltimore, Maryland, United States
Massachusette General Hospital
🇺🇸Boston, Massachusetts, United States
Massachussetts General Hospital
🇺🇸Boston, Massachusetts, United States
DFCI/Pharmacy (Drug Shipment Only)
🇺🇸Boston, Massachusetts, United States
Lawrence and Idell Weisberg Cancer Treatment Center
🇺🇸Farmington Hills, Michigan, United States
Siteman Cancer Center- West County
🇺🇸Creve Coeur, Missouri, United States
Barnes-Jewish Hospital
🇺🇸St. Louis, Missouri, United States
Washington University, School of Medicine
🇺🇸St. Louis, Missouri, United States
Siteman Cancer Center
🇺🇸St. Peters, Missouri, United States
NSLIJ Health System/Monter Cancer Center
🇺🇸Lake Success, New York, United States
Dartmouth Hitchcock Medical Center
🇺🇸Lebanon, New Hampshire, United States
Memorial Sloan-Kettering Cancer Center: Rockefeller Outpatient Pavilion
🇺🇸New York, New York, United States
Columbia University Medical Center
🇺🇸New York, New York, United States
Department of Medicine MSG at SUNY HSC at Syracuse, INC., d/b/a University Physicians
🇺🇸Syracuse, New York, United States
University of California, Los Angeles
🇺🇸Santa Monica, California, United States
Memorial Cancer Institute (West)
🇺🇸Pembroke Pines, Florida, United States
Ingalls Memorial Hospital
🇺🇸Harvey, Illinois, United States
UC Davis Cancer Center
🇺🇸Sacramento, California, United States
University of California Davis Medical Center
🇺🇸Sacramento, California, United States
Drug Shipping for Yale; C/O Thomas Ferencz, RPh, BCOP
🇺🇸New Haven, Connecticut, United States
Smilow Cancer Hospital at Yale New Haven
🇺🇸New Haven, Connecticut, United States
Clinical Trial Office
🇺🇸New Haven, Connecticut, United States
Yale Cancer Center
🇺🇸New Haven, Connecticut, United States
Investigational Drug Service, Pharmacy Department, UNC Hospitals
🇺🇸Chapel Hill, North Carolina, United States
UNC Health Care, NC Cancer Hospital Infusion/lnpatient Pharmacy (CHIP)
🇺🇸Chapel Hill, North Carolina, United States
UNC Hospitals
🇺🇸Chapel Hill, North Carolina, United States
Tuen Mun Hospital, Department of Clinical Oncology
🇭🇰Tuen Mun, New Territories, Hong Kong
Dr. Georges-L. Dumont Regional Hospital
🇨🇦Moncton, New Brunswick, Canada
Swedish Medical Center
🇺🇸Seattle, Washington, United States
Office of Dr. John McWhae
🇨🇦Calgary, Alberta, Canada
Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada
Spetsializirana Bolnitsa za Aktivno Lechenie po Onkologiya, Klinika po himioterapiya
🇧🇬Sofia, Bulgaria
Hopital Notre-Dame du Centre Hospitalier de l'Universite de Montreal (CHUM)
🇨🇦Montreal, Quebec, Canada
Pharmacy Aseptic Service Unit
🇮🇪Galway, Ireland
MDOZS "Dr. Marko Markov", Otdelenie po onkoterapiya i paliativni grizhi
🇧🇬Varna, Bulgaria
Memorial Sloan-Kettering Cancer Center
🇺🇸New York, New York, United States
St. Mary's Hospital Center
🇨🇦Montreal, Quebec, Canada
Debreceni Egyetem Orvos- és Egészségtudományi Centrum, Tudogyogyaszati Klinika
🇭🇺Debrecen, Hungary
Aseptic Compounding Unit
🇮🇪Dublin 8, Ireland
State Medical Institution "Oncology Center #2" of Healthcare Department of Krasnodar Region
🇷🇺Sochi, Russian Federation
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
Royal Victoria Hospital
🇨🇦Montreal, Quebec, Canada
Department of Clinical Oncology, Prince of Wales Hospital
🇭🇰Shatin, New Territories, Hong Kong
Veszprem Megyei Onkormanyzat Tudogyogyintezete
🇭🇺Farkasgyepu, Hungary
Fejer Megyei Szent Gyorgy Korhaz, Pulmonologiai Osztaly
🇭🇺Szekesfehervar, Hungary
National Cancer Center Hospital East
🇯🇵Kashiwa, Chiba, Japan
National Hospital Organization Hokkaido Cancer Center
🇯🇵Sapporo, Hokkaido, Japan
Hyogo Cancer Center
🇯🇵Akashi, Hyogo, Japan
Okayama University Hospital
🇯🇵Okayama-city, Okayama, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
Universitair Medisch Centrum Groningen
🇳🇱Groningen, Netherlands
Pracownia Optyczna Bozena Lawrynowicz Optyk Dyplomowany
🇵🇱Olsztyn, NAP, Poland
Centrum Medyczne Ars Medica
🇵🇱Olsztyn, NAP, Poland
Wojewodzki Szpital Specjalistyczny w Olsztynie
🇵🇱Olsztyn, NAP, Poland
Uniwersyteckie Centrum Kliniczne
🇵🇱Gdansk, Poland
Orszagos Koranyi TBC és Pulmonologiai Intezet, VI. Bronchologia
🇭🇺Budapest, Hungary
Hospital de Navarra
🇪🇸Pamplona, Navarra, Spain
Division of Respiratory and Critical Care Medicine, Department of Medicine, Queen Mary Hospital
🇭🇰Pokfulam, Hong Kong